期刊
ANNALS OF HEMATOLOGY
卷 89, 期 5, 页码 453-458出版社
SPRINGER
DOI: 10.1007/s00277-009-0864-x
关键词
Acute myeloid leukemia; Prognostic factor; Intermediate-risk cytogenetics; BAALC
类别
资金
- Spanish Fondo de Investigaciones Sanitarias de la Seguridad Social [PI061351, 00/0023-00]
- Gerencia Regional de Salud, Junta Castilla y Leon [89/A/06]
- CIC, IBMCC (USAL-CSIC), Spain
We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据